The efficacy of a molecule active at metabolic, neurotransmitter and membrane levels was evaluated in a group of 20 patients with typical involutional symptoms, who came under the care of the rehabilitation therapist for their concomitant decrease of motor activities. All subjects were treated with 1.5 g/day L-acetylcarnitine per os for 6 months, and subjected to the evaluation of cognitive ability (MMS), depression (HDRS), and behavioral and self-sufficiency performances (SCAG), at baseline (t0), after 90 days (t1), and after 180 days (t2). Whereas the basal evaluation showed disorders at all levels, the treatment gave a statistically significant improvement of all performances at both t1 and t2, achieving an effective recovery of the patients' quality of life, an improved participation in family and social life, and a diminished inertness in motor activity, which was the reason why they were studied.
|Number of pages||4|
|Journal||Drugs under Experimental and Clinical Research|
|Publication status||Published - 1988|
ASJC Scopus subject areas
- Molecular Medicine
- Pharmacology (medical)
- Drug Discovery